Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Internal and Emergency Medicine
Published in: Internal and Emergency Medicine 4/2014

01-06-2014 | Letter to the Editor

Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule

Authors: Paul Christiaan Dirk Bank, Henk-Jan Guchelaar, Joachim Jesse Swen

Published in: Internal and Emergency Medicine | Issue 4/2014

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Magnani E, Farnetti E, Nicoli D et al (2013) Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule. Intern Emerg Med 8(5):417–423PubMedCrossRef
2.
Swen JJ, Nijenhuis M, de Boer A et al (2011) Pharmacogenetics: from bench to byte—an update of guidelines. Clin Pharmacol Ther 89(5):662–673PubMedCrossRef
3.
Caudle KE, Thorn CF, Klein TE et al. (2013) Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther 94(6):640–645
4.
Deenen MJ, Cats A, Sechterberger MK et al. (2011) Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of PDYD in fluoropyrimidine therapy. J Clin Oncol 29 (suppl abstract 3606)
5.
Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA (2013) DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics 14(11):1255–1272PubMedCrossRef
Metadata
Title
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase (DPD) splice site variant: the need for further revision of dose and schedule
Authors
Paul Christiaan Dirk Bank
Henk-Jan Guchelaar
Joachim Jesse Swen
Publication date
01-06-2014
Publisher
Springer Milan
Published in
Internal and Emergency Medicine / Issue 4/2014
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-013-1027-6

Other articles of this Issue 4/2014

Internal and Emergency Medicine 4/2014 Go to the issue

IM - ORIGINAL

Delirium in elderly patients hospitalized in internal medicine wards

EM - ORIGINAL

High-frequency transducers for point-of-care ultrasound applications: what is the optimal frequency range?

IM - Case Record

A man with low cholesterol and weakness of the lower limbs

IM - ORIGINAL

Cherry-tree colon: colonoscopic appearance suggesting drug-induced mucosal injury

CE - LETTER TO THE EDITOR

Hypokalemia-induced rhabdomyolysis

IM - ORIGINAL

Improved survival in limited scleroderma-related pulmonary artery hypertension
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits